GlassScriptPhysician profile
Ashley Anne Byrnes
NPI 1255900882
$2,177.28
in general payments reported to CMS, 2019-2025
20 companies · $892 in 2025
The $892 reported for 2025 was more than what 85% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $223 · 2022: $418 · 2023: $487 · 2024: $157 · 2025: $892.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,536.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,535.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $696.41 | 2021-2025 | |
| Merz North America, INC. | $485.25 | 2025 | |
| Collegium Pharmaceutical, INC. | $245.07 | 2022-2025 | Belbuca |
| Ibsa Pharma INC. | $169.03 | 2022-2025 | Flector, Licart, Tirosint |
| Averitas Pharma INC. | $84.95 | 2023-2024 | Qutenza |
| Amgen INC. | $70.46 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $52.86 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $50.48 | 2021 | |
| Lilly USA, LLC | $47.50 | 2021-2022 | |
| Depuy Synthes Sales INC. | $35.39 | 2023-2024 | Orthovisc, Monovisc |
| Teva Pharmaceuticals USA, INC. | $32.86 | 2022-2025 | Ajovy |
| Avanir Pharmaceuticals, INC. | $31.66 | 2022 | |
| Allergan, INC. | $29.37 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $28.20 | 2025 | |
| Horizon Therapeutics Plc | $24.99 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $21.95 | 2023 | Quviviq |
| Otsuka America Pharmaceutical, INC. | $20.80 | 2023 | Nuedexta |
| Pfizer INC. | $19.02 | 2023 | |
| Braeburn INC. | $18.33 | 2023 | Brixadi |
| Ferring Pharmaceuticals INC. | $12.70 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Byrnes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.